Why the study?
Does subcutaneous low-molecular-weight heparin reduce recurrent thrombotic events and bleeding compared to intravenous unfractionated heparin in patients with proximal deep vein thrombosis?
Does subcutaneous low-molecular-weight heparin reduce recurrent thrombotic events and bleeding compared to intravenous unfractionated heparin in patients with proximal deep vein thrombosis?
Answers are grounded in this paper and cite their sources.
This historical review highlights a landmark trial demonstrating that subcutaneous LMWH is at least as effective and safe as intravenous UFH for DVT, which paved the way for outpatient management without laboratory monitoring.
How we changed our approach to venous thromboembolism TITLE Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis.
No takes yet. Share an insight, caveat, or question.
Walter Ageno (2022) conducted an editorial in Proximal deep vein thrombosis (n=170). Subcutaneous low-molecular-weight heparin (nadroparin) vs. Intravenous unfractionated heparin (target aPTT 1.5-2.0 times pretreatment value) was evaluated on Recurrent thrombotic events at 6 months.
Synapse has enriched 10 related papers. Consider them for comparative context: